6:35 PM
 | 
Dec 15, 2011
 |  BC Extra  |  Top Story

InterMune falls on Esbriet assessment

InterMune Inc. (NASDAQ:ITMN) was off $5.55 (30%) to $12.74 on Thursday after Germany's health technology assessment agency said Esbriet pirfenidone provides "no additional benefit" compared with best supportive care in patients with idiopathic pulmonary fibrosis (IPF). The Institute for Quality and Efficiency in Health Care (IQWiG) said in its preliminary benefit assessment report...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >